Table 6.

Oral side effects of Slovak healthcare workers who received BNT162b2 and stratified by gender, February–March 2021 (n = 522).

Variable	Outcome	Female (n = 402)	Male (n = 120)	Total (n = 522)	Sig.
Oral Side Effect Prevalence	Ulcers	8 (2%)	2 (1.7%)	10 (1.9%)	1.000
	Vesicles	6 (1.5%)	2 (1.7%)	8 (1.5%)	1.000
	Blisters	8 (2%)	3 (2.5%)	11 (2.1%)	1.000
	White/Red Plaque	6 (1.5%)	1 (0.8%)	7 (1.3%)	1.000
	Angular Cheilitis	6 (1.5%)	0 (0%)	6 (1.1%)	0.345
	Halitosis	6 (1.5%)	1 (0.8%)	7 (1.3%)	1.000
	Xerostomia	2 (0.5%)	0 (0%)	2 (0.4%)	1.000
	Burning/Bleeding Gingiva	16 (4%)	1 (0.8%)	17 (3.3%)	0.139
	Taste Disturbance	1 (0.2%)	0 (0%)	1 (0.2%)	1.000
	Oral Paraesthesia	4 (1%)	0 (0%)	4 (0.8%)	0.578
	Intensity (0–10)	0.16 ± 0.54	0.08 ± 0.36	0.14 ± 0.51	0.118
	Total (n)	43 (10.7%)	7 (5.8%)	50 (9.6%)	0.112
Oral Side Effect Onset	1–3 days	9 (21.4%)	1 (14.3%)	10 (20.4%)	0.467
	1st Week	8 (19%)	2 (28.6%)	10 (20.4%)	1.000
	2nd Week	9 (21.4%)	1 (14.3%)	10 (20.4%)	0.467
	3rd Week	11 (26.2%)	2 (28.6%)	13 (26.5%)	0.742
	4th Week	5 (11.9%)	1 (14.3%)	6 (12.2%)	1.000
Ulcers, Vesicles, and Blisters Location (n = 15)	Tongue	4 (36.4%)	0 (0%)	4 (26.7%)	0.516
	Palate	2 (18.1%)	1 (25%)	3 (20%)	1.000
	Labial/Buccal Mucosa	6 (54.5%)	1 (25%)	7 (46.7%)	0.569
	Gingiva	3 (27.3%)	2 (50%)	5 (33.3%)	0.560
	Lips	1 (9.1%)	1 (25%)	2 (13.3%)	0.476
White or Red Plaque Location (n = 7)	Tongue	4 (66.7%)	0 (0%)	4 (57.1%)	0.429
	Soft Palate	1 (16.7%)	1 (100%)	2 (28.6%)	0.286
	Labial/Buccal Mucosa	2 (33.3%)	0 (0%)	2 (28.6%)	1.000

Chi-squared test (χ²), Fisher’s exact test, and Mann–Whitney test (U) were used with a significance level (Sig.) of < 0.05.